Press Releases

FORT LAUDERDALE, Florida, May 15, 2020 — (BUSINESS WIRE) — ImmunSYS, Inc., a clinical- stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that results from a proof of concept (PoC) study evaluating its proprietary immunotherapy platform, YourVaccx™, for the treatment of patients with metastatic solid tumor cancers will be …

ImmunSYS Announces Upcoming Presentation at AACR Virtual Annual Meeting II Read More »

FORT LAUDERDALE, Florida, June 11, 2020 — ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, announced today the appointment of George C. Prendergast, PhD, a leading researcher and pioneer in immune therapies, to their scientific advisory board, effective April 2020. “We are honored to welcome Dr. Prendergast to …

ImmunSYS Welcomes George C. Prendergast, PhD, a Renowned
Cancer Immunology Expert, to its Scientific Advisory Board Read More »

– In 18 evaluable patients with metastatic prostate cancer, 50% had a                            Complete Response (CR) and 62% had post-therapy PSA reductions of ≥ 50%– FORT LAUDERDALE, Florida, June 22, 2020 — (BUSINESS WIRE) — ImmunSYS, Inc., a clinical stage biopharmaceutical company focused on the …

50% Complete Response Rate Observed in YourVaccx™ Study for Patients with Metastatic Prostate Cancer was Presented at the AACR Virtual Annual Meeting II Read More »

FORT LAUDERDALE, Florida, July 13, 2020 — ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that it hosted a virtual Analyst Day event on Tuesday, July 7th, 2020. Eamonn Hobbs, Chairman and CEO of ImmunSYS and Charles J. Link, Jr., M.D., Chief Medical Officer and President …

ImmunSYS Announces it Hosted a Virtual Analyst Day Event on July 7, 2020 Read More »